Journal Article Research Support, Non-U.S. Gov't Epublish 5 citations
PubMed: 36845120 DOI: 10.3389/fimmu.2023.971277
Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach.
Front Immunol 14:971277
Authors: Erin C Williams, Alexander Kizhner, Valerie S Stark, Aria Nawab, Daniel D Muniz, Felipe Echeverri Tribin, Juan Manuel CarreƱo, Dominika Bielak, Gagandeep Singh, Michael E Hoffer, Florian Krammer, Suresh Pallikkuth, Savita Pahwa
Affiliations
- Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, United States.
- Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.
- Department of Biomedical Engineering, University of Miami, Miami, FL, United States.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, FL, United States.
- Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Abstract
Introduction
The influence of pre-existing humoral immunity, inter-individual demographic factors, and vaccine-associated reactogenicity on immunogenicity following COVID vaccination remains poorly understood.
Methods
Ten-fold cross-validated least absolute shrinkage and selection operator (LASSO) and linear mixed effects models were used to evaluate symptoms experienced by COVID+ participants during natural infection and following SARS-CoV-2 mRNA vaccination along with demographics as predictors for antibody (AB) responses to recombinant spike protein in a longitudinal cohort study.
Results
In previously infected individuals (n=33), AB were more durable and robust following primary vaccination when compared to natural infection alone. Higher AB were associated with experiencing dyspnea during natural infection, as was the total number of symptoms reported during the COVID-19 disease course. Both local and systemic symptoms following 1 and 2 dose (n=49 and 48, respectively) of SARS-CoV-2 mRNA vaccines were predictive of higher AB after vaccination. Lastly, there was a significant temporal relationship between AB and days since infection or vaccination, suggesting that vaccination in COVID+ individuals is associated with a more robust immune response.
Discussion
Experiencing systemic and local symptoms post-vaccine was suggestive of higher AB, which may confer greater protection.
MeSH
Immunity, Humoral, Sars-Cov-2, Vaccines, Rna, Messenger, Vaccination, Signs And Symptoms, Immune System Diseases, Immunity, Severe Acute Respiratory Syndrome-Related Coronavirus, Demography, Infections